November 2025

Week in Review: CMS to cover cardiac ablations in ASCs | Abbott's safety concerns | FDA clears new TAVR guidewire ()
Robotic aortic valve replacement gaining momentum | Key takeaways from TCT 2025 | Repairing two valves at once ()
AI dramatically improves heart attack detection | FDA clears coronary plaque analysis software | Heartflow takes on PCI planning ()
New guidance covers ablations in ASCs | Gregg Stone on ATHENS-HF | Abbott's warning after deaths | IVC filter recalled ()
MPFS cuts cardiologist pay | New ablation policy a 'tremendous victory' | Medtronic's strong quarter | Medline files for IPO ()
CMS to cover cardiac ablations performed in ASCs | FDA clears TAVR guidewire | A new way to repair 2 heart valves at once ()
News Alert: CMS to cover cardiac ablations performed in ambulatory surgical centers ()
The first heart device of its kind | Stem cell patch impresses | FDA sees promise in new therapy | MAC linked to major risks ()
Medtronic beats expectations | GLP-1 drugs & stroke | Historic hospital pauses transplant program | Boston Scientific & Epic ()
Week in Review: Myval TAVR valve's strong performance | Drones deliver AEDs | Did Boston Scientific make the right call? ()
AI flags high-risk coronary plaques | Siemens Healthineers & Boston Scientific work together | FDA clears new software ()
FDA clears smart shirt | Did Boston Scientific make the right call on TAVR? | Progress for heart failure drug | Beta-blockers ()
CCTA in the cath lab | Medicare covers renal denervation | Biodegradable device shows promise | TCT 2025 | Is fasting necessary? ()
Drones deliver AEDs in US | European study finds cost savings of early TAVR in asymptomatic AS | Flurpiridaz sees rapid growth ()
SCAI says noncompete contracts are unfair to cardiologists | Cash prizes raise medication adherence | INOCA device raises $23M ()
Indian-made TAVR valve outperforms Sapien, Evolut | Apple Watch Faces import ban over oximetry| Billing codes added for DCB ()
Reducing lactate to improve cardiogenic shock outcomes | Siemens and Boston Scientific ICE partnership | New cloud CVIS system ()
Top 10 most popular cardiology video interviews this past month ()
Week in Review: The cath labs of the future | ‘Unprecedented’ results for new therapy | Robotic aortic valve replacement ()
New-onset AFib after CABG | Key EP policies | PFA for ventricular tachycardia shows early potential ()
FDA clears ‘thermometer of the future’ | Coffee may reduce AFib risk | $64M raised for shock drug | AI outperforms risk scores ()
New drug recalls | Gene-editing therapy lowers cholesterol & more | 'The less you drink, the better' | Trump's health questioned ()
Rising interest in RAVR | FDA clears tech for heart surgery | CAC & noncardiac risks | PPM after TAVR | 'Cardiology deserts’ ()
Gene-editing therapy delivers 'unprecedented' results | SCAI fights for interventional cardiologists | AI for STEMI detection ()
FDA clears Stereotaxis robotic system | Heart patient sues Abbott | 3D echo in the congenital OR | New-onset AFib after CABG ()
A trend to watch in cardiology | FDA clears new-look robotic system | ‘Father of ECMO’ remembered | Pill lowers cholesterol ()
FDA clears AI-powered imaging software | PE thrombectomy use skyrockets | Startup seeks approval | Bleeding risks & TAVR ()
The cath labs of the future | Melatonin linked to heart risks | GLP-1 drugs & healthy choices | Key FDA approval not unanimous ()
Week in Review: How the MPFS impacts cardiology | New recalls | PE thrombectomy on the rise | Stem cell patch impresses ()
Q&A: What we know and don’t know about PFA | Judge files lawsuit | Good news for renal denervation | First-in-human IVL data ()
Insulin pumps recalled | Large-scale changes fail to boost outcomes | EP town hall coming soon | Transcaval access for Impellas ()
Stem cell patch shows promise | Key takeaways from STORM-PE | FDA panel to review new device | Is fasting necessary? | MAC & HF ()
TAVR Highlights: A key PARTNER 3 update | Medtronic launches new guidewire | How to minimize bleeding risks | SGLT2 inhibitors ()
FDA highlights new Class I recall | Startup co-founded by cardiologist emerges from stealth with big plans | IVL data ()
October's Top Stories: Statin recalled | Concerns about TAVR in low-risk patients | Trump's health | Compensation hits new high ()
Cardiology groups criticize Medicare fee schedule "efficiency" payment reduction | PE thrombectomy increases 700% ()
New device tariffs? | Pushback against Trump's visa fee | Medicare covers renal denervation | FDA approves labeling changes ()
ACC shares policy concerns | Bidding war for startup gets ugly | Bleeding risks after TAVR | Viral infections & vaccination ()
Week in Review: Medicare covers renal denervation | In-person coverage of TCT 2025 | Patient sues Abbott | FDA clears software ()